CHDI Foundation, Inc. Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2013
NCT02061722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

18f-mni-659 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Huntington Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1